• MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.

Insights

Heart Failure With Preserved Ejection Fraction: Current Status and Future Opportunities

EP. 1: Heart Failure Clinical and Economic Burden
EP. 1: Heart Failure Clinical and Economic Burden
EP. 2: The Progressive Nature of Heart Failure
EP. 2: The Progressive Nature of Heart Failure
EP. 3: Link Between LVEF, NT-ProBNP and Cardiac Remodeling
EP. 3: Link Between LVEF, NT-ProBNP and Cardiac Remodeling
EP. 4: Improved Understanding of Heart Failure
EP. 4: Improved Understanding of Heart Failure
EP. 5: Treatment Goals for Patients With Heart Failure
EP. 5: Treatment Goals for Patients With Heart Failure
EP. 6: The HFrEF Standard of Care
EP. 6: The HFrEF Standard of Care
EP. 7: Heart Failure Management Unmet Needs
EP. 7: Heart Failure Management Unmet Needs
EP. 8: Utilization Management Strategies for Appropriate Treatment
EP. 8: Utilization Management Strategies for Appropriate Treatment
EP. 9: Challenges in the Management of HFpEF
EP. 9: Challenges in the Management of HFpEF
EP. 10: Differences in Standard of Care: HFpEF vs HFrEF
EP. 10: Differences in Standard of Care: HFpEF vs HFrEF
EP. 11: Ensuring Timely and Appropriate Access to Therapy
EP. 11: Ensuring Timely and Appropriate Access to Therapy
EP. 12: Differences in Economic Burden: HFpEF and HFrEF
EP. 12: Differences in Economic Burden: HFpEF and HFrEF
EP. 13: PROVE-HF Trial Overview
EP. 13: PROVE-HF Trial Overview
EP. 14: PARAGON-HF Trial Overview
EP. 14: PARAGON-HF Trial Overview
EP. 15: Recent Findings from the PARALLAX Study
EP. 15: Recent Findings from the PARALLAX Study
EP. 16: Promising Findings From the TOPCAT Study
EP. 16: Promising Findings From the TOPCAT Study
EP. 17: Differences in Leading Treatments for Heart Failure
EP. 17: Differences in Leading Treatments for Heart Failure
EP. 18: When to Add an SGLT2 Inhibitor to Treatment Regimen
EP. 18: When to Add an SGLT2 Inhibitor to Treatment Regimen

New Directions in Chemotherapy-Induced Neutropenia

EP. 1: Facts About Chemotherapy-Induced Neutropenia
EP. 1: Facts About Chemotherapy-Induced Neutropenia
EP. 2: Chemotherapy-Induced Neutropenia: Impact on Cancer Care
EP. 2: Chemotherapy-Induced Neutropenia: Impact on Cancer Care
EP. 3: Monitoring for Chemotherapy-Induced Neutropenia
EP. 3: Monitoring for Chemotherapy-Induced Neutropenia
EP. 4: Considerations for Chemotherapy-Induced Neutropenia Prophylaxis
EP. 4: Considerations for Chemotherapy-Induced Neutropenia Prophylaxis
EP. 5: Chemotherapy-Induced Neutropenia Prophylaxis: Standard of Care
EP. 5: Chemotherapy-Induced Neutropenia Prophylaxis: Standard of Care
EP. 6: CIN Prophylaxis: Treating With G-CSFs
EP. 6: CIN Prophylaxis: Treating With G-CSFs
EP. 7: Plinabulin With G-CSF Treatment for CIN Prophylaxis
EP. 7: Plinabulin With G-CSF Treatment for CIN Prophylaxis
EP. 8: CIN Prophylaxis: NCCN’s Reactions to COVID-19
EP. 8: CIN Prophylaxis: NCCN’s Reactions to COVID-19
EP. 9: Chemotherapy-Induced Neutropenia: Financial Burden
EP. 9: Chemotherapy-Induced Neutropenia: Financial Burden
EP. 10: Health Plans React to Chemotherapy-Induced Neutropenia
EP. 10: Health Plans React to Chemotherapy-Induced Neutropenia
EP. 11: Reducing the Risk of Chemotherapy-Induced Neutropenia
EP. 11: Reducing the Risk of Chemotherapy-Induced Neutropenia
EP. 12: At-Home Administration of CIN Prophylaxis
EP. 12: At-Home Administration of CIN Prophylaxis
EP. 13: Coverage for Chemotherapy-Induced Neutropenia
EP. 13: Coverage for Chemotherapy-Induced Neutropenia

CAR T-Cell Therapy for the Management of Multiple Myeloma

EP. 1: Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
EP. 1: Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
EP. 2: Healthcare Utilization for Relapsed/Refractory MM Patients
EP. 2: Healthcare Utilization for Relapsed/Refractory MM Patients
EP. 3: Treatment Gaps in Relapsed/Refractory MM
EP. 3: Treatment Gaps in Relapsed/Refractory MM
EP. 4: A Better Understanding of Relapsed/Refractory MM
EP. 4: A Better Understanding of Relapsed/Refractory MM
EP. 5: CAR T-Cell Therapy in Relapsed/Refractory MM
EP. 5: CAR T-Cell Therapy in Relapsed/Refractory MM

Defining Value for the Treatment of Brain Metastases in Metastatic HER2-Positive Breast Cancer

EP. 1: Progression of HER2+ mBC
EP. 1: Progression of HER2+ mBC
EP. 2: HER2+ mBC: Diagnosing Patients With Brain Mets
EP. 2: HER2+ mBC: Diagnosing Patients With Brain Mets
EP. 3: Monitoring Brain Mets in HER2+ mBC
EP. 3: Monitoring Brain Mets in HER2+ mBC
EP. 4: Healthcare Utilization for HER2+ mBC With Brain Mets
EP. 4: Healthcare Utilization for HER2+ mBC With Brain Mets
EP. 5: Treatment Beyond Second-line Therapy in HER2+ mBC
EP. 5: Treatment Beyond Second-line Therapy in HER2+ mBC
EP. 6: Managing At-Risk Patients for Brain Mets in HER2+ mBC
EP. 6: Managing At-Risk Patients for Brain Mets in HER2+ mBC
EP. 7: HER2CLIMB Study
EP. 7: HER2CLIMB Study
EP. 8: Phase 2 LANDSCAPE Trial
EP. 8: Phase 2 LANDSCAPE Trial
EP. 9: Phase 3 NALA Study
EP. 9: Phase 3 NALA Study
EP. 10: Phase 2 DESTINY-Breast01 Trial
EP. 10: Phase 2 DESTINY-Breast01 Trial
EP. 11: Value of Emerging Agents in HER2+ mBC
EP. 11: Value of Emerging Agents in HER2+ mBC
EP. 12: Sequencing HER2-targeted Agents in mBC
EP. 12: Sequencing HER2-targeted Agents in mBC
EP. 13: Approaching At-Risk Patients for Brain Mets in HER2+ mBC
EP. 13: Approaching At-Risk Patients for Brain Mets in HER2+ mBC
EP. 14: Impact of Early Identification of Brain Mets
EP. 14: Impact of Early Identification of Brain Mets
EP. 15: Patient-Centered Care for Treatment of Brain Mets
EP. 15: Patient-Centered Care for Treatment of Brain Mets
EP. 16: Payer Perspective: Impact of COVID-19 on Treatment of mBC
EP. 16: Payer Perspective: Impact of COVID-19 on Treatment of mBC
EP. 17: Impact of COVID-19 and Future of mBC Treatment
EP. 17: Impact of COVID-19 and Future of mBC Treatment

Challenges and Opportunities for Patients With HIV During COVID-19

EP. 1: The Impact of COVID-19 on the HIV Community
EP. 1: The Impact of COVID-19 on the HIV Community
EP. 2: HIV and Risk of COVID-19
EP. 2: HIV and Risk of COVID-19
EP. 3: Healthcare Disparities and HIV During COVID-19
EP. 3: Healthcare Disparities and HIV During COVID-19
EP. 4: Diagnosing HIV During COVID-19
EP. 4: Diagnosing HIV During COVID-19
EP. 5: HIV Prescribing Patterns During COVID-19
EP. 5: HIV Prescribing Patterns During COVID-19
EP. 6: Managing HIV During COVID-19
EP. 6: Managing HIV During COVID-19
EP. 7: PrEP Therapy for HIV and COVID-19
EP. 7: PrEP Therapy for HIV and COVID-19
EP. 8: PrEP Adherence During COVID-19
EP. 8: PrEP Adherence During COVID-19
EP. 9: HIV Treatment Adherence and COVID-19
EP. 9: HIV Treatment Adherence and COVID-19
EP. 10: Managing HIV In the Future: Lessons from COVID-19
EP. 10: Managing HIV In the Future: Lessons from COVID-19

Current and Future Treatments for the Management of Myelodysplastic Syndrome

EP. 1: An Overview of Myelodysplastic Syndrome
EP. 1: An Overview of Myelodysplastic Syndrome
EP. 2: Understanding Myelodysplastic Syndrome's Nature as Cancer
EP. 2: Understanding Myelodysplastic Syndrome's Nature as Cancer
EP. 3: Myelodysplastic Syndrome: Diagnosis and Risk Stratification
EP. 3: Myelodysplastic Syndrome: Diagnosis and Risk Stratification
EP. 4: Clinical Burden of Myelodysplastic Syndrome
EP. 4: Clinical Burden of Myelodysplastic Syndrome
EP. 5: Economic Burden of Myelodysplastic Syndrome
EP. 5: Economic Burden of Myelodysplastic Syndrome
EP. 6: Myelodysplastic Syndrome: Goals of Therapy
EP. 6: Myelodysplastic Syndrome: Goals of Therapy
EP. 7: MDS Management: Use of Bone Marrow Transplantation
EP. 7: MDS Management: Use of Bone Marrow Transplantation
EP. 8: Therapies and Treatment Regimens for MDS
EP. 8: Therapies and Treatment Regimens for MDS
EP. 9: Hypomethylating Agents in MDS Management
EP. 9: Hypomethylating Agents in MDS Management
EP. 10: MDS Management: Use of Transfusion Alongside HMAs
EP. 10: MDS Management: Use of Transfusion Alongside HMAs
EP. 11: Potential Complications of Transfusions in MDS Management
EP. 11: Potential Complications of Transfusions in MDS Management
EP. 12: MDS Management: Challenges With Chemotherapy
EP. 12: MDS Management: Challenges With Chemotherapy
EP. 13: MDS Management: ASCERTAIN Equivalence Study
EP. 13: MDS Management: ASCERTAIN Equivalence Study
EP. 14: Oral HMAs in MDS Management: Adherence and Accessibility
EP. 14: Oral HMAs in MDS Management: Adherence and Accessibility
EP. 15: Oral HMAs in MDS: Personal Experience and Future Directions
EP. 15: Oral HMAs in MDS: Personal Experience and Future Directions
EP. 16: MDS: Access to Care and Other Ongoing Challenges
EP. 16: MDS: Access to Care and Other Ongoing Challenges
EP. 17: Practical Advice for Managing Myelodysplastic Syndrome
EP. 17: Practical Advice for Managing Myelodysplastic Syndrome